The FDA has granted orphan drug designation to namodenoson (CF102) in pancreatic cancer. Orphan drug designation provides Can ...

Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented ...

Mirvetuximab soravtansine (Elahere) is an antibody-drug conjugate designed to treat ovarian cancer. It works by binding to folate receptor-alpha (FRα). This binding delivers a potent anticancer drug ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from ...

The CHRYSALIS-2 study (NCT04077463) evaluated the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, ...

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local ...